CVS Omnicare pharmacy in Vegas is first to join new pharmacy union

The CVS pharmacy logo is displayed on a sign above a CVS Health Corp. store in Las Vegas, Nevada on February 7, 2024. Patrick T. Fallon | AFP | Getty Images A CVS in Las Vegas has become the first location to join a new national pharmacy union, a milestone as organizers try to help … Read more

FDA approves Pfizer gene therapy Beqvez for treatment of hemophilia B

Pavlo Gonchar | Lightrocket | Getty Images The Food and Drug Administration on Friday approved Pfizer‘s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.  The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B … Read more

Bristol Myers Squibb (BMY) earnings Q1 2024

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and some new drugs posted sales growth. But the pharmaceutical company swung to … Read more

Merck (MRK) earnings Q1 2024

Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey. Spencer Platt | Getty Images Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products. The pharmaceutical giant also raised and narrowed its … Read more

Walgreens launches cell, gene therapies in service expansion

A person rides past a Walgreens truck, owned by the Walgreens Boots Alliance, in Manhattan, New York City, on Nov. 26, 2021. Andrew Kelly | Reuters Walgreens on Thursday said it will start to work directly with drugmakers to bring cell and gene therapies to U.S. patients as part of a broader expansion of its specialty … Read more

Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.

The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company Novo Nordisk. Joel Saget | AFP | Getty Images The U.S. Senate has launched an investigation into the high price of Novo Nordisk‘s popular weight loss and diabetes drugs Ozempic and Wegovy in the United States. The investigation into the Danish drugmaker was announced by … Read more

Here are health-care stocks to watch now, amid a bumpy recovery

The Good Brigade | Digitalvision | Getty Images Health care, long an ailing stock market sector, has recovered over the past six months, with currently robust vital signs and strong growth projections. The recovery comes after the sector failed to make good on positive expectations for 2022 based on estimates of pent-up demand for physician … Read more

Biogen (BIIB) earnings Q1 2024

A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected. Biogen and … Read more

3.6 million Medicare patients could get heart health coverage

More than 3 million people with Medicare could be eligible for coverage of Wegovy now that the blockbuster weight loss drug is also approved in the U.S. for heart health, according to an analysis released Wednesday by health policy research organization KFF. But some eligible beneficiaries could still face out-of-pocket costs for the highly popular … Read more

Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs

Signage for Novartis AG at a building in the company’s headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.  Bloomberg | Bloomberg | Getty Images Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals Tuesday, after the company raised its full-year guidance following better-than-expected first-quarter results. The stock pared gains … Read more